Drug Profile
CGP 49689
Latest Information Update: 17 May 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 17 May 2001 Profile reviewed but no significant changes made
- 14 Mar 1995 No-Development-Reported for HIV infections treatment in Switzerland (Unknown route)